| 3 | 1/1 | 返回列表 |
| 查看: 851 | 回復(fù): 2 | |||
小木蟲劉樹青木蟲 (著名寫手)
夜未眠
|
[求助]
求大神翻譯 只有一段哦,謝謝
|
|
In the future, it is likely that ctDNA and CTCs will have complementary roles as cancer biomarkers although separate approaches may have distinct advantages in specificclinicalcontexts. ctDNA analysis is appealing due to the ease with which plasma can be collected and analyzed without the prior need to enrich and isolate a rare population of cells. For this reason, ctDNA analysis is likely to be the preferred option for genotyping and monitoring treatment response. The analysis of ctDNA can be applied as a high-throughput strategy for the assessment of clinical samples, but is limited to the analysis of point mutations, structural rearrangements, copy number aberrations and changes in DNA methylation. In contrast, the analysis of CTCs provides the unique opportunity to study the whole cell, allowing DNA, RNA and protein-based molecular profiling, and the opportunity for functional studies to guide personalized treatment selection. Although the analysis of both ctDNA and CTCs pose several technical challenges, ongoing improvements are expected over coming years, and both approaches hold great promise as biomarkers in various facets of cancer management. Technological advances might allow in the future, the use of a liquid biopsy (CTCs or ctDNA) for earlier cancer diagnosis or detection of disease relapse/progression. However, it is not known if earlier detection will lead to improved patient outcomes. This will become possible only if effective treatments are available to target early recurrences. Another open question is whether the liquid biopsy will complement analysis of primary tumor or metastases for tailoring treatment selection. Ongoing interventional clinical trials using CTC detection and characterization by CellSearch® will provide initial answers on the above question. Future research will be focused on optimizing and standardizing new technologies for both ctDNA and CTC analysis, demonstrating appropriate analytical and clinical validity as well as establishing the clinical utility of ctDNA and CTC testing through appropriately designed prospective clinical trials. |

金蟲 (正式寫手)
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 070300化學(xué)求調(diào)劑 +3 | 苑豆豆 2026-03-20 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 一志愿西安交通大學(xué)材料工程專業(yè) 282分求調(diào)劑 +10 | 楓橋ZL 2026-03-18 | 12/600 |
|
|
[考研]
|
.6lL 2026-03-18 | 8/400 |
|
|
[考研] 一志愿華南師大 070300(化學(xué))304分求調(diào)劑 +3 | 0703武芊慧雪304 2026-03-18 | 3/150 |
|
|
[考研] 一志愿 西北大學(xué) ,070300化學(xué)學(xué)碩,總分287,雙非一本,求調(diào)劑。 +3 | 晨昏線與星海 2026-03-18 | 3/150 |
|
|
[考研] 材料專業(yè)求調(diào)劑 +6 | hanamiko 2026-03-18 | 6/300 |
|
|
[考研] 22408 344分 求調(diào)劑 一志愿 華電計算機(jī)技術(shù) +4 | solanXXX 2026-03-20 | 4/200 |
|
|
[考研] 南京大學(xué)化學(xué)376求調(diào)劑 +3 | hisfailed 2026-03-19 | 6/300 |
|
|
[考研] 323求調(diào)劑 +3 | 洼小桶 2026-03-18 | 3/150 |
|
|
[考研] 求調(diào)劑,一志愿:南京航空航天大學(xué)大學(xué) ,080500材料科學(xué)與工程學(xué)碩,總分289分 +4 | @taotao 2026-03-19 | 4/200 |
|
|
[考研] 085600材料與化工 +8 | 安全上岸! 2026-03-16 | 8/400 |
|
|
[考研] 中南大學(xué)化學(xué)學(xué)碩337求調(diào)劑 +3 | niko- 2026-03-19 | 6/300 |
|
|
[考研] 求調(diào)劑 +3 | eation27 2026-03-20 | 3/150 |
|
|
[考研] 086500 325 求調(diào)劑 +3 | 領(lǐng)帶小熊 2026-03-19 | 3/150 |
|
|
[考研] 085410人工智能專碩317求調(diào)劑(0854都可以) +4 | xbxudjdn 2026-03-18 | 4/200 |
|
|
[考研] 生物學(xué)調(diào)劑招人。! +3 | 山海天嵐 2026-03-17 | 4/200 |
|
|
[考研] 0703化學(xué)調(diào)劑 +5 | pupcoco 2026-03-17 | 8/400 |
|
|
[考研] 材料專碩306英一數(shù)二 +10 | z1z2z3879 2026-03-16 | 13/650 |
|
|
[考研] 312求調(diào)劑 +8 | 陌宸希 2026-03-16 | 9/450 |
|
|
[考研]
|
zhouzhen654 2026-03-16 | 3/150 |
|